The aims of this research designed the new mono-carbonyl analogs of curcumin (MACs), synthesize the molecules then determine its activity in cyclooxygenase inhibition in vitro and in silico. New design mono-carbonyl analogs of curcumin performed by QSAR study using the BuildQSAR program. 2,6-bis-(3'-ethoxy, 4-hydroxybenzylidene)-cyclohexanone; 2,6-bis-(3'-Bromo, 4'-methoxybenzylidene)-cyclohexanone and 2,6-bis-(3',4'-dimethoxybenzylidene)-cyclohexanone had been synthesized using aldol condensation reaction. The anti-inflammatory assay performed using measuring the level of malondialdehyde (MDA). In silico studies were carried out to evaluate the activity of cyclooxygenase inhibition in cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) specific proteins. Molecular operating environment (MOE) program used for protocol docking. The results of the QSAR study reveal the good relationship of anti-inflammatory activities. The in vitro anti-inflammatory activities of 6-bis-(3'-ethoxy, 4'-hydroxybenzylidene)-cyclohexanone; 2,6-bis-(3'-Bromo, 4'-methoxybenzylidene)-cyclohexanone and 2,6-bis-(3',4'-dimethoxybenzylidene)-cyclohexanone indicates the promising potential to inhibit cyclooxygenase enzyme with IC50 13.53μM, 11.56μM, 20.52μM respectively. The in silico evaluation showing that O atoms (47, from ketones) of 2,6-bis-(3'-Bromo, 4'-methoxybenzylidene)-cyclohexanone interacts with ARG120 and TYR355 through H acceptor.
Key words: In silico, in vitro, mono-carbonyl analogues of curcumin, anti-inflammatory, cyclooxygenase inhibition
|
